MacroGenics reports Q2 FY25 results, cash runway through 2027.

• MacroGenics reports Q2 2025 financial results • Cash, cash equivalents, and marketable securities: $176.5 million • Cash runway through H1 2027 • Received $70 million upfront payment from Sagard Healthcare Partners • CEO Eric Risser outlines strategic priorities for 2025 and 2026

Title: MacroGenics Reports Q2 2025 Financial Results

MacroGenics Inc. (NASDAQ: MGNX), a biotechnology company focused on antibody-based cancer treatments, reported its second-quarter (Q2) 2025 financial results on August 14, 2025. The company reported GAAP revenue of $22.2 million, which fell short of Wall Street's GAAP projection of $31.7 million, marking a significant increase of 105.6% year-over-year (YoY) from $10.8 million in Q2 2024. Despite the revenue growth, the company's loss per share (GAAP) was $(0.57), missing the $(0.42) GAAP EPS expected by analysts [1].

The company's cash position declined from $201.7 million as of December 31, 2024, to $176.5 million as of June 30, 2025. This decrease was partially offset by a $70 million upfront payment received from Sagard Healthcare Partners under a royalty purchase agreement for ZYNYZ, a cancer immunotherapy [1]. The company's cash runway is projected to extend through the first half of 2027, assuming projected payments from partners and ongoing cost savings [1].

MacroGenics' new CEO, Eric Risser, who assumed the role on August 13, 2025, outlined strategic priorities for 2025 and 2026. Risser, who has extensive experience in the biotech and pharmaceutical industry, emphasized the company's focus on advancing its research-stage pipeline, attracting new partnerships, and securing regulatory approvals. He also underscored the importance of cost discipline and asset monetization [1, 2].

The company's revenue mix in Q2 2025 was driven primarily by contract manufacturing and collaboration income. Contract manufacturing revenue (GAAP) was $15.4 million, up from $2.9 million in Q2 2024, while revenue from collaborations (GAAP) rose to $6.9 million from $2.2 million in Q2 2024. These increases partially offset the complete loss of product revenue following the exit from MARGENZA in November 2024 [1].

Research and development expenses (GAAP) decreased to $40.8 million, primarily due to reduced costs related to vobramitamab duocarmazine development and lower manufacturing and IND-enabling costs for MGC028. Selling, general, and administrative expenses (GAAP) also decreased to $9.3 million, reflecting lower professional fees and the absence of product commercialization costs [1].

Investors should watch for the outcome of critical regulatory milestones with ZYNYZ and TZIELD, as well as updates on clinical progress for leading pipeline candidates. The company's reliance on partnerships and asset monetizations for funding means future revenue streams may vary significantly from quarter to quarter and remain hard to predict [1].

References:
[1] https://www.nasdaq.com/articles/macrogenics-revenue-doubles-q2
[2] https://www.stocktitan.net/news/MGNX/